A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

NCT01092104 | Completed Phase 1 DMC

• 1 other identifier: 652-2-201
• Study Type: interventional
• Target: 52
• Locations: 0 countries
• Sites: N/A

Brief Summary

A double-blind, randomized, placebo-controlled, dose-escalating study to assess the antiviral activity, safety, tolerability, and pharmacokinetics (PK) of the CCR5 antagonist TBR 652 monotherapy dosed orally once daily (QD) for 10 days in HIV 1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naïve patients.

Conditions

HIV-1 Infection

Outcome Measures

Primary Outcomes (1)

• HIV-1 RNA Change from Baseline

  10 days

Study Arms (6)

TBR-652 25 mg QD

EXPERIMENTAL

TBR 25 mg QD for 10 days

Drug: TBR-652

Placebo

PLACEBO COMPARATOR

Matching Placebo QD for 10 days

Drug: TBR-652 Matching Placebo

TBR-652 50 mg QD

EXPERIMENTAL

TBR-652 50 mg QD for 10 days

Drug: TBR-652 50 mg

TBR-652 75 mg QD

EXPERIMENTAL

TBR-652 75 mg QD for 10 days

Drug: TBR-652 75 mg

TBR-652 100 mg QD

EXPERIMENTAL

TBR-652 100 mg QD for 10 days

Drug: TBR-652 100 mg

TBR-652 150 mg

EXPERIMENTAL

TBR-652 150 mg QD for 10 days

Drug: TBR-652 150 mg

Interventions

TBR-652 DRUG

TBR-652 25 mg

TBR-652 25 mg QD

TBR-652 Matching Placebo DRUG

Matching Placebo

Placebo

TBR-652 50 mg DRUG

TBR-652 50 mg QD for 10 days

TBR-652 50 mg QD

TBR-652 75 mg DRUG

TBR-652 75 mg QD for 10 days

TBR-652 75 mg QD

TBR-652 100 mg DRUG

TBR-652 100 mg QD for 10 days

TBR-652 100 mg QD

TBR-652 150 mg DRUG

TBR-652 150 mg QD for 10 days

TBR-652 150 mg

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• No clinically significant findings on Screening evaluations (clinical, laboratory, and ECG), which in the opinion of the Investigator would interfere with the subject's ability to comply with the protocol.
• Antiretroviral treatment-experienced; no antiretroviral therapy for at least 6 weeks prior to study entry.
• CCR5 antagonist therapy naive.
• CD4 cell count \>/= 250 cells/mm3 during Screening (within 30 days prior to first dose).
• Two separate qualifying plasma HIV 1 RNA levels \>/= 5,000 copies/mL within 45 days prior to first dose.
• Females who are not of reproductive potential (documented to be surgically sterile or postmenopausal \[defined as amenorrhea ≥ 1 year and follicle stimulating hormone {FSH} ≥ 30 mU/mL\]).
• Females of child-bearing potential may be enrolled following a negative serum pregnancy test. If participating in activity that could lead to pregnancy, males and females shall agree to use two forms of barrier method contraception during the trial and for 2 months after stopping the medication.

You may not qualify if:

• Presence of CXCR4- or dual/mixed-tropic HIV 1 virus.
• Active CDC category C disease (except cutaneous Kaposi's sarcoma not requiring systemic therapy during the trial).
• History of infection with hepatitis B or hepatitis C virus, history of cirrhosis, or any known active or chronic liver disease. NOTE: Hepatitis B vaccinated patients are eligible.
• Serum ALT or AST values greater than Grade 1 or bilirubin values greater than the upper limit of normal (ULN) at Screening.
• History of HIV-2.
• Recent history (\< 30 days prior to study drug administration) of clinically significant infection.
• Pregnant females or females who are breastfeeding.
• Treatment with immunomodulating agents (such as systemic corticosteroids, interleukins, interferons) or any agent with known anti-HIV activity within 30 days prior to study drug administration.
• Treatment with any vaccine within 30 days of study drug administration.
• A positive pre-study drug screen, including amphetamines, barbiturates, cocaine, or PCP.
• Anticipated use of antacids during the trial and/or within 7 days prior to first dose of study drug.
• Current alcohol or drug use, which in the expert judgment of the investigator, will interfere with the patient's ability to comply with the protocol requirements.
• Inability, in the opinion of the investigator, to comply with the dosing schedule and protocol evaluations.
• Use of any experimental medications within 4 weeks prior to Screening.
• Current (within 30 days prior to the first dose of study drug) or anticipated use of antimetabolites; alkylating agents; or drugs, herbal preparations, and foods (including grapefruit) known to affect the CYP 3A4 or CYP 2C8 enzymes or P-glycoprotein transporters.

Sponsors & Collaborators

• Tobira Therapeutics, Inc.: lead

Related Publications (2)

• Lalezari J, Gathe J, Brinson C, Thompson M, Cohen C, Dejesus E, Galindez J, Ernst JA, Martin DE, Palleja SM. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):118-25. doi: 10.1097/QAI.0b013e318213c2c0.

  PMID: 21317794 RESULT

• Marier JF, Trinh M, Pheng LH, Palleja SM, Martin DE. Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naive patients. Antimicrob Agents Chemother. 2011 Jun;55(6):2768-74. doi: 10.1128/AAC.00713-10. Epub 2011 Apr 12.

  PMID: 21486960 RESULT

MeSH Terms

Interventions

cenicriviroc

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 22, 2010
• First Posted: March 24, 2010
• Study Start: February 1, 2009
• Primary Completion: November 1, 2009
• Study Completion: November 1, 2009
• Last Updated: July 10, 2013

Record last verified: 2013-07